Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 30;75(2):477–482. doi: 10.1161/HYPERTENSIONAHA.119.13642

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors.

Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

PMC Copyright notice

Figure 3. — The effect of canakinumab on clinical events stratified by baseline systolic blood pressure. Major adverse cardiovascular events (MACE), myocardial infarction, coronary revascularization, stroke, heart failure hospitalization, and mortality adjusted for age, sex, body mass index, LDL (low-density lipoprotein)-Cholesterol, and diabetes mellitus (placebo n=3344, canakinumab n=6717, number of events indicated by box size, hazard ratio indicated by box position with 95% CI, Q1: lowest baseline systolic blood pressure, Q4: highest baseline systolic blood pressure, <1 favors canakinumab). HR indicates hazard ratio.